Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock

Official title

Efficacy of Early Argipressin (Arginine Vasopressin) in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock: a Multicentric Randomized, Double-blind Placebo-controlled Superiority Trial

Overview

Acute circulatory failure (shock) is defined as insufficient oxygen transport to meet the oxygen requirements of organs and tissues. Vasoplegic shock is the most frequent cause of shock, defined by vasoplegia and a drop in arterial pressure with preserved cardiac output. The main aetiologies of vasoplegic shock are sepsis and post-operative vasoplegia. Symptomatic treatment of vasoplegic shock is based on vasopressors. The first-line vasopressor is norepinephrine. Refractory vasoplegic shock refers as high norepinephrine requirements. In patients with catecholamine-refractory vasoplegia, the use of vasopressin as a second-line treatment is proposed. The use of vasopressin could improve organ and tissue perfusion, improve renal function, accelerate shock reversal and reduce patients' exposure to catecholamines, and thus to their side effects. Currently, there is a gap between evidence and guidelines/practice regarding vasopressin in patients with refractory vasoplegic shock: 1. There are no large randomized control trial focusing on vasopressin use in patients with refractory vasoplegic shock and data extrapolated from non-refractory shock have contradictory conclusions regarding the benefit of vasopressin in this population. 2. In patients with vasoplegic shock, expert often recommend vasopressin as second line vasopressor and, in the case of septic shock, current international guidelines clearly position vasopressin as second-line therapy in septic shock and advocate its initiation in patients with vasoplegia refractory to norepinephrine. The strengh of those recommendation is weak due to moderate quality of evidence highlighting the need to conduct a large randomized control trial on this topic. We hypothesize that the use of vasopressin in patients with refractory vasoplegic shock may improve 30-day survival, decrease renal replacement therapy and reduce duration of vasopressor administration. This is the first multicentred study aiming to confirm the superiority of vasopressin in combination with norepinephrine over norepinephrine alone in this population.

Interventions

• Drug Argipressin
  Argipressin 0.4 U.ml-1 (i.e. 40IU diluted in 100ml 0.9% NaCl bag)
• Drug Chlorure de sodium
  NaCl 0.9%
• Other Collection of clinical data
  At inclusion, D0 to D7, ICU discharge, D30 and D90

Primary outcome measures

• The mortality rate [Time frame: At Day 30]
• The use of renal replacement therapy within 30 days post-inclusion [Time frame: At Day 30]
• The persistence of vasopressor use within 15 days post-inclusion [Time frame: At Day 15]

Eligibility criteria

Inclusion criteria

• Patients aged ≥ 18 years
• Vasoplegic shock defined as patient requiring vasopressor at the time of inclusion AND with a cardiac index ≥ 2.3/L/min/m² \[32\] (measured by echocardiography, Swan-Ganz, pulse contour analysis or thermodilution) and with hyperlactatemia > 2 mmol/l.
• Vasoplegia must be primarily caused by one of the following etiologies:

• Sepsis (documented or clinically suspected infection)
• Post-operative vasoplegia (following cardiac or non-cardiac surgery)
• Post hemorrhage
• Sterile systemic inflammation (e.g., pancreatitis, burns, trauma)
• Anaphylaxis
• Liver failure
• Other causes of vasoplegia
• Refractory shock: dose of vasopressor (express as norepinephrine base equivalent) ≥ 0.25 μg/kg/min in order to maintain perfusion pressure within patient-defined targets (defined by the physician in charge of the patient).
• Early intervention: Criteria for refractory AND vasoplegic shock reached for less than 12 hours.
• Informed consent obtained from the patient or, if unable to give consent, a surrogate. If the surrogate is not available, emergency consent can be considered.
• Covered by French national health insurance

Exclusion criteria

• Patients that do not present the criteria for vasoplegic AND refractory shock at the time of inclusion anymore (resolved condition)
• Ongoing vasopressin treatment
• Ongoing inotrope treatment (except norepinephrine)
• Ongoing acute coronary syndrome, mesenteric ischemia
• Uncontrolled active bleeding
• Vasoplegia due to neurogenic shock
• Vasospastic disease (Raynaud's disease, systemic scleroderma…)
• Hyponatremia <120 mmol l-1
• Known hypersensitivity to Argipressin or to any of the excipients of REVERPLEG®.
• Patient already enrolled in an interventional trial
• Decision to limit life-sustaining treatments
• Person under legal protection
• Pregnant, parturient or breastfeeding women

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Double blind

Primary purpose

Treatment

Study locations

France · 1 center

• CHU Dijon Bourgogne — Dijon

Identifiers

NCT: NCT07063680 · NGUYEN PHRCN 2023

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗